Recombinant protein production is a cornerstone of research and key to the development of diagnostics and therapeutics. From the advent of recombinant insulin production in 1982, protein expression and purification techniques have continuously improved. On average, the FDA has approved 44 protein-based therapeutics per year for the past 5 years, including monoclonal antibodies for the treatment of disease, growth factors, thrombolytics, and immunomodulators (FDA, 2020). These join a growing list of enzymes, reagents, and food additives that aid industrial and academic processes alike (Arbige et al., 2019;Pham, 2018). For the expression of these proteins, non-native expression systems offer unparalleled control on the production process compared to endogenous protein extraction protocols. This is because the user is able to tailor the cultivation parameters for each protein target by adjusting variables like the media composition, pH, agitation, aeration, temperature, cell density, inducer concentration, induction time, and feeding strategy (Ahmad et al., 2018). In particular, bacterial expression systems benefit from short doubling times, inexpensive media, genetic tractability, and ease of scaling up. Nonetheless, most bacterial laboratory strains lag behind eukaryotic expression systems in their ability to efficiently introduce posttranslational modifications (PTMs) onto a polypeptide backbone, and as such they are rapidly falling out of use. Indeed, during the 2014-2018 period, the use of non-mammalian systems for protein expression saw the largest drop on record to